rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SPRO
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Spero Therapeutics at guggenheim conference: SP001 drives next phase
      Nov 10Investing.comSPRO
      This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
      Oct 28BenzingaSPRO
      Spero Therapeutics COO Timothy Keutzer to retire at year-end, will serve as consultant
      Oct 27Investing.comSPRO
      Spero Therapeutics names regulatory chief, COO to retire
      Oct 26Investing.comSPRO
      Spero Therapeutics Targets 2027 Phase II Launch for SP001 in IgG4-Related Disease
      Oct 21Yahoo FinanceSPRO
      Spero Therapeutics at Chardan conference: cash-rich bet on SP001
      Oct 20Investing.comSPRO
      Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight
      Oct 12Yahoo FinanceSPRO
      H.C. Wainwright raises Spero Therapeutics price target to $6
      Sep 14Investing.comSPRO

      This is the newest page. Registered accounts read further back.